THE MANAGEMENT OF ASTHMA General principles:
The participants felt that the stepped care approach advocated in previous guidelines may have been counter-productive by promoting an overly rigorous stratification of levels of asthma care. The concept of the asthma continuum was therefore adopted to reflect a more dynamic therapeutic approach, which allows drug therapy to be adapted to the severity of the underlying illness while facilitating adjusting the intensity of therapy to the degree of control (see below) achieved at any one time. This concept is outlined in Figure 1 .
The severity of asthma in an individual patient is judged by the frequency and chronicity of symptoms, the presence of persistent airflow limitation and the medication required to maintain control. In all but those patients with mild or intermittent disease, asthma severity can best be evaluated after an aggressive trial of therapy with inhaled corticosteroids (minimum of beclomethasone 200 m g or the equivalent in children and 400 m g minimum in adolescents and adults) or a course of oral corticosteroids in more troublesome cases. Signs of severe or poorly controlled asthma include the occurrence of a prior near-fatal episode (loss of consciousness, intubation), recent hospitalization or emergency room visit, night time symptoms, limitation of daily activities, need for inhaled beta 2 -agonist several times per day or at night, and forced expiratory volume in 1 s (FEV 1 ) or peak expiratory flow (PEF) less than 60% predicted. Furthermore, asthma severity is likely to vary over time; this is of special importance in children in whom asthma often improves with age, suggesting the need to attempt a reduction in medication when asthma ceases to be troublesome.
Diagnosis:
Objective measurements are needed to confirm the diagnosis of asthma and to assess asthma severity. The diagnosis of asthma should be confirmed objectively in all but the most trivially symptomatic subjects [Level 3A] . Objective documentation of variable airflow obstruction can be obtained by one or more of the following means.
Recommendations: i) FEV 1 : variable airflow obstruction can be documented by spontaneous variability in FEV 1 or by improvement 15 mins after inhaled beta 2 -agonist administration. (The term beta 2 -agonist refers to short-acting inhaled agents throughout this document unless stated otherwise.) A 12% or greater improvement in FEV 1 (at least 180 mL) after beta 2 -agonist administration is considered significant [Level 1A] . Changes in FEV 1 that occur over time, without any specific therapeutic intervention or after a prolonged course of oral (more than one week) or inhaled corticosteroids (more than two weeks), should demonstrate an increase of at least 20% (minimum 250 mL) [Level 2A] . ii) PEF: home measurement of PEF, incorporating response to inhaled beta 2-agonist, may be used to document variable airflow obstruction. A mean percentage difference between the highest and lowest of four PEF values (AM and PM pre-and post-bronchodilator on the same day) of 20% or more over a period of several weeks is indicative of asthma [Level 2A] . With less reliability, a 20% or greater improvement in PEF 15 mins after the administration of 200 to 400 m g inhaled salbutamol or the equivalent may be used as an indicator of asthma in the physician's office when spirometry is not available [Level 3B]. iii) Airway hyperresponsiveness: in subjects with a normal FEV 1 , excessive bronchoconstrictor responsiveness can be documented by finding hyperresponsiveness to histamine or methacholine. The test is usually only available in specialized centres and this may limit its utility to the primary care physician. Assessment of bronchial hyperresponsiveness may be useful in subjects who, despite normal airway calibre, require excessive medication for symptom control or fail to respond to therapy [Level 3A] . Such an objective measure of airway responsiveness may help the physician to correlate symptoms with the degree of airway hyperresponsiveness or to verify the diagnosis or etiology of the patient's symptoms.
Special considerations in children:
Pharmacological reversibility of airway obstruction as a method of diagnosing asthma is controversial when dealing with infants and toddlers, though less so among those with recurrent wheezing. Furthermore, the relationship between asthma and airway hyperresponsiveness in preschool children is less straightforward than in older subjects. In addition, wheezing disorders are very common in infancy and for the majority of children; this will disappear with age without residual 'asthma'. In children who cannot perform reliable pulmonary function tests (most commonly spirometry), consensus was that the likelihood of asthma increases with the presence of an increasing number of the following features: wheezing occurring after the age of one year, accompanied by attacks of dyspnea, or more than three times per year (especially if not related to a viral illness); severe episodes of dyspnea and wheezing; prolonged cough, most notably occurring with physical activity or disturbing sleep; evidence of atopic diathesis in the child or his or her direct family; symptomatic or objective evidence of improvement with asthma therapy; and parental smoking [Level 3B]. Based upon the concept of the asthma continuum, once best results have been defined and achieved in the individual patient, medication should be reduced to the lowest possible dose with the aim to remain within the parameters of control outlined in Table 2 (see also Figure 2 Respiratory irritants: These are encountered both indoors and outdoors. Air pollution is the principal outdoor irritant and the constituents linked to exacerbations of asthma are, in order of importance, respirable particulates, ground-level ozone and sulphur dioxide. Indoor irritants, especially second-hand tobacco smoke, appear to represent an even greater hazard to the health of the asthmatic in the context of the Canadian climate. Among other indoor irritants, the strongest evidence for an etiological role in asthma is available for the oxides of nitrogen. Various types of indoor air cleaners are available and, while several have been shown to reduce levels of irritants significantly, health benefits have yet to be consistently demonstrated.
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Can Aero-allergens: Allergen exposure plays a pivotal role in the development and exacerbation of asthma among atopic subjects, ie, in the majority of asthmatics. Exposure to aeroallergens at an early age may be especially important for the development of asthma that persists into later childhood. The indoor allergens derived from furred pets, especially cats, and dust mites contribute most to asthma morbidity. Indoor and outdoor exposure to moulds may also be of significance.
Minimizing excess humidity indoors is a simple way of reducing contamination by dust mites and indoor moulds.
Recommendations:
i) There is a clear need to identify allergens to which a subject has become sensitized and to institute a systematic program to eliminate or, at least, substantially reduce such exposures [Level 1A] . ii) Dust mite control measures are effective in improving asthma among patients sensitized to these allergens [Level 1B]. iii) The reduction of exposure to cat allergen cannot be achieved without removing the pet from the home [Level 2B]. iv) Humidity in the home, including the asthmatic's bedroom, should be kept below 50% [Level 2A].
Occupational asthma: Asthma may be related to work by several means: 1. Exposure to irritants such as fumes, vapours or dusts may trigger bronchospasm in subjects with pre-existing asthma; 2. Single acute exposure to high levels of an irritant vapour, fume or smoke has been associated with the development of asthma in previously normal subjects. This condition is called reactive airways dysfunction syndrome (RADS); 3. Finally, occupational asthma (OA) is the most frequent occupational pulmonary disease and is defined as asthma that is induced by exposure to a specific sensitizing agent found in the work place (excluding irritant induced bronchospasm). The importance of identifying subjects with OA lies in the fact that progressive deterioration and even permanent disability may occur if exposure is continued after the onset of symptoms. Conversely, early withdrawal may be associated with disappearance of symptoms and airway hyperresponsiveness. It is important to note that the presence of asthma before encountering an occupational exposure to a sensitizing agent does not preclude the development of true OA.
Recommendations: i) Asthmatics should not be exposed to irritant levels higher than the threshold limit value (the airborne concentration to which nearly all workers may be exposed repeatedly without ill effects), although even this limit may not be safe in subjects with severe airway hyperresponsiveness [Level 3B]. ii) An occupational history is warranted in all adults with asthma [Level 3A]. iii) The diagnosis of true OA secondary to exposure to a sensitizing substance at work needs to be objectively established. The gold standard for diagnosis is a specific inhalation challenge in the laboratory or workplace [Level 2B].
Viral infections -role in asthma:
Intermittent episodes of cough and wheezing are often associated with viral and sometimes mycoplasma infections in children. Lung function and airway responsiveness may be adversely affected for weeks after such infections. Respiratory syncytial virus (RSV), in particular, is associated with bronchitis in infancy and with recurrent bouts of wheezing. It is not clear whether RSV 'induces' asthma or selects predisposed infants, or both. There is evidence to support both points of view. Recurrent viral induced wheezing is thought to decrease in frequency and severity with time. The degree of personal or family atopy helps predict the likelihood that wheezing will be persistent. Figure 2 , an inhaled corticosteroid is the single best agent for bringing and keeping asthma under control [Level 1A]. As well, inhaled corticosteroids may improve the prognosis of this condition over the long term [Level 2A] . Issues of long term safety, especially with the use of high doses of inhaled corticosteroids in children, must be considered. For this reason, some participants felt that in children with mild asthma, a trial of inhaled cromoglycate could be given or could be substituted for low dose inhaled corticosteroids once adequate control of asthma is achieved. Among infants, a similar role to cromoglycate was suggested for ketotifen.
DRUG THERAPY OF ASTHMA As illustrated in
Most important, the pathophysiology of asthma consists of inflammation and smooth muscle spasm localized to the airways. For this reason, and in order to limit untoward effects of drug therapy, the inhaled route of delivery of medications is preferred in most situations.
Recommendations for therapy with corticosteroids:
i) In adults and older children, the initial recommended dose of inhaled corticosteroids for mild to moderate asthma is in the range of 400 to 1000 m g daily of beclomethasone or budesonide on a twice daily basis. The added dose of inhaled steroid required will depend both on the severity of the exacerbation and the intensity of maintenance therapy. For most exacerbations among patients taking the equivalent of inhaled beclomethasone 1500 m g per day or less in whom the episode is not too severe (those able to carry out activities of daily living, using fewer than 12 puffs of short acting beta 2 -agonist per day providing at least 3 h of relief, and FEV 1 or PEF 60% or more of baseline), the dose of inhaled corticosteroids can be increased two-to fourfold (taken qid) [Level 3B]. The dose of inhaled steroid should be reduced to the usual maintenance dose over a period of several weeks once best results are again observed. iv) If the attack is more severe, ie, FEV 1 or PEF below 60% of best or the response to an increased dose of inhaled corticosteroids is inadequate, a course of oral prednisone (0.5 to 1 mg/kg/day) is usually required and should last a full two weeks in adults. 
Safety of inhaled corticosteroids:
At doses up to 1000 m g/ day of beclomethasone or the equivalent in adults and 400 m g/day in pre-adolescent children, the adverse effects of inhaled corticosteroids may constitute a nuisance but are very rarely associated with significant systemic effects. Corticosteroid induced skin thinning and bruising indicate chronic systemic steroid activity, but are generally not clinically important unless patients are receiving greater than the equivalent of 1000 m g inhaled beclomethasone/day or repeated courses of oral corticosteroids. The total combined daily doses of oral and inhaled corticosteroids interact to increase the risk of hypothalamic-pituitary adrenal suppression. The additive effect of nasal corticosteroids may also have to be considered. Oral candidiasis and dysphonia are not uncommon local side effects of therapy in adults but are uncommon in children. Growth inhibition is of particular concern in children. The dose at which this may occur will vary according to individual susceptibility, the type of inhaled corticosteroids as well as the delivery device. Clinically significant effects on growth are distinctly unusual at doses less than the equivalent of 400 m g daily of inhaled beclomethasone. Long term use of high doses of inhaled corticosteroids may increase the risk of osteoporosis in high-risk groups.
Recommendations:
i) The lowest dose of inhaled corticosteroids required to maintain good asthma control should be used [Level 1A] . ii) Among patients whose asthma is well controlled, a reduction in the dose of inhaled corticosteroids should be attempted in order to identify the lowest dose required to maintain control. Such an attempt at dose reduction should be on a regular basis [Level 2A]. iii) Local side effects should be minimized by careful mouth rinsing and gargling and by using a large-volume spacer device when the delivery device is a metered-dose inhaler [Level 1A]. iv) Referral to a specialist is recommended in adults when more than 1000 m g of inhaled beclomethasone or its equivalent is required on an ongoing basis. In children, the threshold for referral to a specialist is lower [Level 3A] . v) Inhaled corticosteroids should be continued during pregnancy but the use of the lowest dose consistent with achieving and maintaining optimal asthma control is recommended [Level 3A] . Inhalation of beclomethasone is not associated with the appearance of steroid in breast milk and, therefore, inhaled corticosteroids can be continued during lactation. vi) Routine ophthalmologic surveillance for posterior subcapsular cataracts is not warranted in patients treated with inhaled corticosteroids [Level 2D]. Such an examination may be limited to subjects complaining of a change in visual acuity. vii) An estrogen supplement should be provided in glucocorticoid-treated postmenopausal women, unless a positive contraindication is present [Level 2B]. viii) It is not necessary to monitor patients treated with inhaled steroid for possible adverse effects on serum glucose, electrolytes or lipid levels [Level 3A]. ix) Careful monitoring of patients taking greater than 2000 m g inhaled corticosteroids is warranted to define better the long term effects on bone metabolism [Level 3B]. Anti-allergic agents: Inhaled cromoglycate and nedocromil appear to prevent some of the inflammatory effects that follow exposure to aero-allergens. They have an excellent safety profile but are much less effective than inhaled corticosteroids in controlling airway inflammation. In patients with mild or moderate chronic asthma, cromoglycate or nedocromil provide a modestly effective and extremely safe alternative to low doses of inhaled corticosteroids. There is no proven benefit obtained by adding cromoglycate to an established regimen containing corticosteroids, either inhaled or oral, while nedocromil's ability to facilitate small reductions in steroid dosage in adults with systemic steroid side effects is equivocal.
Ketotifen is an oral antihistamine for which there is evidence of benefit for mild asthma in children under the age of five years and whose route of administration is attractive in this age group.
All three agents have the disadvantage of requiring many weeks of therapy before a beneficial effect on persistent symptoms occurs. For cromoglycate and nedocromil, qid dosing is required, at least initially. None of these agents has any role in the treatment of acute exacerbations of asthma. Long-acting beta 2 -agonists: Published guidelines and reviews have suggested that long-acting beta 2 -agonists (salmeterol and formoterol) can be used as an additional treatment in subjects whose asthma is not adequately controlled with inhaled corticosteroids. The optimal dose of inhaled steroids under which patients should be placed before considering adding an inhaled long-acting beta 2 -agonist is still undetermined. Theophylline and its derivatives: Theophylline remains an effective anti-asthma drug for both children and adults. Advantages include oral administration, relatively low cost and availability of drug monitoring. Its dosing is complicated by numerous factors, including drug interaction, organ dysfunction, age and inter-individual variability. In addition, its use is associated with many potential side effects, most of which are dose related. Common side effects include gastric intolerance, irritability, headaches and insomnia. Patients vary in susceptibility to side effects. Introduction of the drug in small increments often reduces the frequency of reported side effects. Recent studies suggest a possible anti-inflammatory effect of theophylline present at lower serum levels than traditionally targeted. However, the clinical significance of this remains to be demonstrated. Anticholinergics: Quaternary isopropyl derivatives of atropine are the most commonly used anticholinergic bronchodilators. Typically, ipratropium bromide or similar compounds act more gradually than beta 2 -agonists such as salbutamol, fenoterol or terbutaline. Inhaled quaternary anticholinergic bronchodilators offer modest bronchodilation in stable ambulatory asthma patients. These drugs may be of greater value in older patients and in those with a combination of both asthma and chronic obstructive pulmonary disease (COPD). There is little information concerning the use of these agents in the long term treatment of asthma in children. During acute exacerbations, these agents may provide additional bronchodilation to optimal doses of beta 2 -agonists in both adults and children.
Recommendations: i) A trial of one of these agents (ketotifen in infants

Recommendations
Recommendation:
i) Inhaled anticholinergics are not first-line agents for the treatment of asthma, with the rare exception of patients who are unable to tolerate beta 2 -adrenergic bronchodilators [Level 3D].
Nonsteroidal immunosuppressive therapy: Fortunately, potent nonsteroidal immunosuppressant drugs taken systemically for asthma are rarely required for the treatment of asthma. In most instances, they are given in the presence of severe disease usually requiring high dose systemic corticosteroids to maintain control or where, even with such high doses, control is not being achieved or systemic corticosteroid side effects are unacceptable. Drugs in this category act widely with potentially serious side effects. These drugs should not be considered before therapy outlined elsewhere in this document has been carefully applied with particular attention to issues of compliance, environmental control and alternative diagnoses.
Drugs usually considered in this category include methotrexate, cyclosporin, azathioprine, 6-mercaptopurine, colchicine, intravenous gamma globulin and gold salts. Studies using these drugs have been small in number and have had variable results. More information is available for methotrexate and cyclosporine than for others. Most studies have been performed in adults, although two small series have looked at children or adolescents.
Recommendations:
i) These potentially toxic drugs should be reserved for subjects with severe asthma dependent on long term oral corticosteroids [Level 3A] . ii) Because of the nature of the clinical problems associated with severe steroid dependent asthmatics who may require further intervention, these patients should be referred to a specialized centre for management and planning [Level 3A] .
Immunotherapy: This consists of the administration by subcutaneous injection of graded doses of allergenic abstracts. It has been used in the treatment of allergic disease for many decades. Its limited efficacy in asthma as opposed to allergic rhinitis has been recognized for many years. AEROSOL DEVICES FOR ASTHMA The success of aerosol drug therapy for asthma requires that the patient master a complex technique to inhale the drug deeply into the airways. Improper technique is common and as many as 50% of patients with asthma experience problems as a result. Since each aerosol delivery device has different deposition characteristics, it cannot be assumed that the therapeutic and side effect profiles will be the same following the change from one device to another. ASTHMA IN THE ELDERLY Asthma may affect 5% to 8% of the population over 65 years of age. Approximately half of the elderly with asthma developed their disease earlier in life but 2% of the general elderly population will have true late-onset asthma. Asthma is often unrecognized in the elderly and the disease is thus frequently undertreated. Asthma may be triggered or aggravated by medication including the use of acetylsalicylic acid (ASA), nonsteroidal anti-inflammatory drugs or topical (ophthalmic) or systemic beta-blocker medication. A diagnosis of asthma may be readily made in those with a past or family history of the disease who have never smoked. In those without such a history, asthma may be difficult to separate from COPD. It is thus important to conduct a trial of corticosteroid therapy, ensuring that the subject has a stable FEV 1 before commencing the trial, and using an increase of FEV 1 of at least 20% (a minimum of 250 mL) as an indication of steroid response.
Recommendations
Treatment of asthma in the elderly does not differ from that in younger asthmatics, although a higher proportion of elderly asthmatics are likely to require oral or inhaled corticosteroids. As with younger patients, inhaled corticosteroid therapy is preferred in the elderly. Difficulty with the use of metered-dose or dry powder inhalers can generally be overcome by education. Spacers may be used with metered-dose inhalers, and occasionally the addition of devices to assist in activation of inhalers maybe useful. Beta 2 -adrenoreceptor dysfunction occurs in the elderly and may be especially severe in the elderly asthmatic. Nevertheless, inhaled beta 2 -agonists are generally effective and well-tolerated in the elderly. Ipratropium bromide may be useful in those who cannot tolerate or who respond poorly to beta 2 -agonists.
It should not be forgotten that asthma may co-exist with other diseases such as heart failure, sometimes making its diagnosis and treatment more difficult. Also, compliance and comprehension of the appropriate management strategies may be more difficult in the elderly. The elderly are usually on more medication, which tends to affect compliance and give rise to a greater risk of drug interactions.
PATIENT EDUCATION
Considerable research remains to be done to determine the ideal content and methods for asthma education programs; we suggest a pragmatic guide for such programs.
Recommendations:
i) Education is an essential component of asthma management [Level 3A] . In specific settings it has been associated with reduced morbidity due to asthma (Level 1A). ii) Goals of asthma education should be to: a) improve control of the asthma; b) reduce asthma morbidity and mortality; c) improve quality of life and ability to function; d) reduce health care costs. iii) The education program should aim at changing behaviour and improve: a) knowledge; b) compliance with treatment; c) self-assessment abilities; d) patient-health care provider relationships. iv) Education programs should include: a) specific information with a practical goal; b) knowledge focused on self-monitoring and self-regulation of medication; c) discussion of the two main components of asthma, inflammation and bronchoconstriction; d) measures of allergen-avoidance in sensitized patients; e) medication (bronchodilators versus anti-inflammatory agents): effects, indications, side effects; f) how and when to use preventative medications; g) proper use of aerosol delivery devices; h) how to monitor severity of asthma and change therapy with the help of an action plan; i) specific information on food allergy, sulphite or ASA intolerance; j) the hazards of smoking and other irritant exposures to be avoided; k) the role of complicating conditions such as gastroesophageal reflux and sinusitis. v) Methods may vary and the selection of a format may change according to resources and individuals. vi) Frequent evaluation of understanding and application of learned behaviour is necessary. vii) Regular follow-up and communication among the health care providers involved is essential. viii) A list of materials and resources should be given to the asthmatic patient. 
PATIENT ADHERENCE TO TREATMENT
MANAGEMENT DURING HOSPITALIZATION
Although the group did not embark on a major review of the management of acute asthma, it was felt that an area not covered by the Canadian Association of Emergency Physicians guidelines, and which was of some importance, was the in-hospital management of the nonmechanically ventilated patient. 
Recommendations
